Navigation Links
Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments

PITTSBURGH, April 20 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has been selected by the Clinton HIV/AIDS Initiative (CHAI) under its UNITAID-funded projects as the primary supplier of five antiretroviral (ARV) drugs used in second-line HIV/AIDS treatment regimens. Matrix also has been selected as the primary supplier of seven ARVs used for pediatric treatment.

Mylan Vice Chairman and CEO Robert J. Coury said: "I would like to congratulate UNITAID and CHAI on the tremendous impact they have made in fighting the HIV/AIDS epidemic, which continues to present significant challenges on a global scale. Facilitating patient access to affordable, quality treatments has helped transform AIDS from a fatal illness into a manageable chronic condition. Ensuring that access to these treatments continues to expand is a critical piece of solving this crisis. Mylan and Matrix are proud to play an important role in these efforts by supplying a broad portfolio of low cost, high quality products, and we remain committed to further increasing access for patients in developing countries through our innovative science and expertise."

According to the Joint United Nations Program on AIDS (UNAIDS), an estimated 33 million people in the world are infected with HIV, and more than 90% of those patients live in the developing world. Less than 4 million patients globally are receiving treatment; however, approximately 30% of patients in developing countries depend on Matrix ARV products.

Mylan's Chief Operating Officer Heather Bresch added: "Matrix has done a remarkable job developing a world-class ARV business in just a few years. Their emphasis on producing affordable products has significantly reduced the average annual cost per patient of AIDS treatment. I also would like to recognize the efforts of UNITAID and CHAI, which have both worked diligently to increase the supply of effective medicines. Significant progress has been made in dramatically reducing the costs of second-line treatments, and our partnerships with CHAI and other donor organizations will allow us to further reduce the costs of treatments for children. However, there still is much more work to be done. Mylan and Matrix intend to advance our leadership role and partnerships by continuing to produce affordable, high quality ARV products and getting them to those in need."

Matrix's second-line products selected for the 2009 UNITAID-CHAI projects include heat-stable Lopinavir/Ritonavir, Tenofovir and two fixed-dose combinations that use Tenofovir. The seven ARVs for which Matrix was selected under the UNITAID Pediatric Project include several first-line fixed-dose combinations. Patients often use second-line therapies if and when they develop resistance to initially prescribed treatments or experience clinical failures. Fixed-dose combinations are multiple ARV drugs combined into a single pill.


UNITAID is an international drug purchase facility, established to provide long-term, sustainable and predictable funding to increase access and reduce prices of quality drugs and diagnostics for the treatment of HIV/AIDS, malaria and tuberculosis in developing countries. UNITAID-CHAI projects supply ARVs for pediatric and adult second-line treatment in 42 developing countries. The group's efforts account for approximately 75% of funding spent on pediatric ARV treatments and 50% of funding spent on second-line ARV treatments in generic accessible markets.

Matrix and ARVs

Matrix is one of the world's largest producers of API used to manufacture ARVs. In 2007, Matrix launched its FDF ARV franchise and, only two years later, offers 29 FDFs, including most of the currently used first- and second-line treatments. All of Matrix's ARV facilities in India meet World Health Organization (WHO) and U.S. Food and Drug Administration (FDA) quality standards, and the company has strong partnerships with all major funding agencies involved in the procurement of ARVs. In addition to its ARV capabilities, Matrix is the world's third largest manufacturer of API used to produce a broad range of therapies.


Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, visit

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
2. BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis
3. BioNanomatrix Receives New NCI Grant to Support Development of Chip-Based Nanofluidics Systems for Cell Fractionation
4. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
5. TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction
6. Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications
7. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
8. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
9. Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc.
10. Engineers make first active matrix display using nanowires
11. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
Post Your Comments:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
Breaking Biology News(10 mins):